Results 1 to 10 of about 6,670,507 (363)

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Journal of Clinical Oncology, 2021
PURPOSE To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. METHODS A multidisciplinary panel of medical
B. Schneider, J. Naidoo, B. Santomasso, C. Lacchetti, S. Adkins, M. Anadkat, M. Atkins, Kelly J. Brassil, J. Caterino, I. Chau, M. Davies, M. Ernstoff, L. Fecher, M. Ghosh, I. Jaiyesimi, J. Mammen, A. Naing, L. Nastoupil, T. Phillips, Laura D. Porter, C. Reichner, Carole Seigel, Jung-Min Song, A. Spira, M. Suarez‐Almazor, U. Swami, John A Thompson, Praveen Vikas, Yinghong Wang, J. Weber, P. Funchain, Kathryn Bollin   +31 more
semanticscholar   +1 more source

High-Antimicrobial Gallium-Doped Zinc Oxide Thin Films on Bio-Based Poly(Ethylene Furanoate) Substrates for Food Packaging Application

Membranes, 2023
Thin films of gallium-doped zinc oxide (GZO), with a thickness of around fifty nanometers were deposited on bio-based poly(ethylene furanoate) (PEF) substrates by radio-frequency sputtering.
Chaoting Zhu, Danling Ye, Tianqi Zhou, Yashuang Cui, Jianbing Yin   +4 more
doaj   +1 more source

Immune-related adverse events of immune checkpoint inhibitors: a review

Frontiers in Immunology, 2023
Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved.
Qinan Yin, Liuyun Wu, Lizhu Han, Xingyue Zheng, Rongsheng Tong, Lianlian Li, Lan Bai, Y. Bian   +7 more
semanticscholar   +1 more source

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.

Journal of the American Medical Association (JAMA), 2023
This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.
M. Sodhi, R. Rezaeianzadeh, Abbas Kezouh, M. Etminan   +3 more
semanticscholar   +1 more source

Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies

Actas Dermo-Sifiliográficas, 2021
El cáncer constituye una de las principales causas de morbimortalidad en los países desarrollados, con un incremento de la supervivencia debido al advenimiento de nuevas terapias y sus combinaciones1.
A. Freites-Martinez, N. Santana, S. Arias-Santiago, A. Viera   +3 more
semanticscholar   +1 more source

Adverse events: an expensive and avoidable hospital problem

Annals of Medicine, 2022
Introduction Adverse healthcare-related events (AE) entail reduced patient safety. Estimating their frequency, characteristics, avoidability and impact is a means to identify targets for improvement in the quality of care.Methods This was a descriptive ...
Diego San Jose-Saras, José L. Valencia-Martín, Jorge Vicente-Guijarro, Paloma Moreno-Nunez, Alberto Pardo-Hernández, Jesús M. Aranaz-Andres   +5 more
doaj   +1 more source

Adverse Events Related to Tirzepatide

Journal of the Endocrine Society, 2023
Context Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved by the US Food and Drug Administration in May 2022 for patients with type 2 diabetes mellitus (T2DM).
Rahul Mishra, Rishi Raj, Ghada Elshimy, Isain Zapata, Lakshmi Kannan, P. Majety, Dinesh Edem, Ricardo Correa   +7 more
semanticscholar   +1 more source

Bio-based poly(ethylene furanoate)/ZnO transparent thin films with improved water vapor barrier and antibacterial properties for food packaging application

Materials Research Express, 2022
Poly(ethylene furanoate) (PEF) biocomposite films incorporating zinc oxide nanoparticle (ZnO NPs) were prepared using a solvent casting method. The ZnO NPs were homogeneously dispersed within the PEF films with the aid of γ −aminopropyltriethoxylsilane ...
Chaoting Zhu, Jianbing Yin, Zhilong Zhang, Feng Shi   +3 more
doaj   +1 more source

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Journal for ImmunoTherapy of Cancer, 2021
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune ...
J. Brahmer, Hamzah Abu-Sbeih, P. Ascierto, J. Brufsky, L. Cappelli, Frank B. Cortazar, D. Gerber, L. Hamad, Eric D. Hansen, Douglas B. Johnson, M. Lacouture, G. Masters, J. Naidoo, M. Nanni, M. Perales, I. Puzanov, B. Santomasso, S. Shanbhag, Rajeev Sharma, D. Skondra, J. Sosman, M. Turner, M. Ernstoff   +22 more
semanticscholar   +1 more source

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

Pharmaceuticals, 2023
Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype.
Stephanie L. Gu, Tara Maier, Andrea P. Moy, Stephen Dusza, David M. Faleck, Neil J. Shah, Mario E. Lacouture   +6 more
doaj   +1 more source